George J T, Hendrikse M, Veldhuis J D, Clarke I J, Anderson R A, Millar R P
MRC Centre for Reproductive Health, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Diabetes Trials Unit, Endocrinology and Metabolism, Oxford Centre for Diabetes, Oxford, UK.
Clin Endocrinol (Oxf). 2017 May;86(5):731-738. doi: 10.1111/cen.13308. Epub 2017 Mar 26.
Gonadotropin-inhibitory hormone (GnIH, human homologue of RFRP-3) suppresses gonadotropin secretion in animal models, but its effects have not been studied in the human.
We tested the hypotheses that exogenous GnIH inhibits LH secretion (i) in postmenopausal women and (ii) in men concurrently administered exogenous kisspeptin.
Following in vitro and in vivo preclinical studies to functionally characterize the GnIH peptide, a dose-finding study (human GnIH: 1·5-150 μg/kg/h, iv for 3 h) was undertaken, and 50 μg/kg/h selected for further evaluation. Five postmenopausal women were administered 50 μg/kg/h iv infusion for 3 h or vehicle on two separate days. Four men were administered kisspeptin-10 (0·3 μg/kg iv bolus) with simultaneous infusion of GnIH (50 μg/kg/h, iv for 3 h) or vehicle.
Healthy postmenopausal women (mean age 58 ± 2 years, LH: 30·8 ± 2·9 IU/l, FSH: 78·7 ± 6·4 IU/l, oestradiol: <50 pmol/l) and men (39·8 ± 2·1 years, mean total testosterone 12·1 ± 1·8 nmol/l, LH 2·2 ± 0·2 IU/l).
Change in area under curve (AUC) of LH during GnIHvs vehicle.
During GnIH administration in postmenopausal women, LH secretion decreased (ΔAUC: -9·9 ± 1·8 IU/3 h) vs vehicle (ΔAUC: -0·5 ± 1·7 IU/3 h; P = 0·02). Kisspeptin-10-stimulated LH responses in men were not affected by GnIH co-administration (60-min AUC of LH 6·2 ± 0·8 IU/h with kisspeptin-10 alone, 6·3 ± 1·0 IU/h, kisspeptin-10 with GnIH, P = 0·72). Exogenous GnIH was well tolerated, with no adverse events reported.
Gonadotropin-inhibitory hormone decreased LH secretion in postmenopausal women in this first-in-human study. Kisspeptin-stimulated LH secretion in men was not inhibited during concomitant administration of GnIH.
促性腺激素抑制激素(GnIH,RFRP - 3的人类同源物)在动物模型中可抑制促性腺激素分泌,但尚未在人体中进行研究。
我们检验了以下假设,即外源性GnIH(i)在绝经后女性中以及(ii)在同时给予外源性亲吻素的男性中抑制促黄体生成素(LH)分泌。
在对GnIH肽进行功能特性鉴定的体外和体内临床前研究之后,进行了一项剂量探索研究(人GnIH:1.5 - 150μg/kg/h,静脉输注3小时),并选择50μg/kg/h用于进一步评估。5名绝经后女性在两个不同日期分别接受50μg/kg/h静脉输注3小时或安慰剂。4名男性接受亲吻素 - 10(0.3μg/kg静脉推注),同时输注GnIH(50μg/kg/h,静脉输注3小时)或安慰剂。
健康绝经后女性(平均年龄58±2岁,LH:30.8±2.9IU/L,FSH:78.7±6.4IU/L,雌二醇:<50pmol/L)和男性(39.8±2.1岁,平均总睾酮12.1±1.8nmol/L,LH 2.2±0.2IU/L)。
GnIH与安慰剂相比,LH曲线下面积(AUC)的变化。
在绝经后女性给予GnIH期间,LH分泌减少(ΔAUC:-9.9±1.8IU/3小时),而给予安慰剂时(ΔAUC:-0.5±1.7IU/3小时;P = 0.02)。在男性中,亲吻素 - 10刺激的LH反应不受同时给予GnIH的影响(单独给予亲吻素 - 10时LH的60分钟AUC为6.2±0.8IU/h,亲吻素 - 10与GnIH同时给予时为6.3±1.0IU/h,P = 0.72)。外源性GnIH耐受性良好,未报告不良事件。
在这项首次人体研究中,促性腺激素抑制激素降低了绝经后女性的LH分泌。在同时给予GnIH期间,亲吻素刺激的男性LH分泌未受到抑制。